By Pat Anson, Editor
A day after saying it wanted to restrict access to hydrocodone, the Food and Drug Administration has approved a new more powerful version of the opioid painkiller that some critics say is dangerous.
Zohydro, which was developed by San Diego based Zogenix Inc. (NASDAQ: ZGNX), will be the first pure hydrocodone painkiller sold in the U.S. Combination versions of hydrocodone, such as Vicodin, typically contain acetaminophen and require dosing every 4 to 6 hours. Extended release Zohydro could be taken just twice a day for chronic pain.
“Zohydro ER will offer prescribers an additional therapeutic option to treat pain, which is important because individual patients may respond differently to different opioids,” the FDA said in a statement.
Zohydro will be classified as a Schedule II drug, which means it can only be dispensed through a physician’s written prescription and no refills will be allowed. There are also more stringent recordkeeping, reporting, and security requirements for Schedule II drugs.
Read more at National Pain Report.
(0) Readers Comments
November 12, 2012
October 08, 2012
September 12, 2012
July 23, 2012
June 11, 2019
April 05, 2019
April 01, 2019
March 18, 2019
Oh boy...Your right we hate to hear this. You know why people in pain
Doesn't the 1.5 billion is spent a year give credence to its possitive
Many MS drugs cause PML and deaths too these drugs all need t
I knew him when he was breaking in at a couple of Los Angeles TV stati
Saying there is a 'twist' is the worst type of spoile